Prevention and Treatment of Multiple Sclerosis (MS) by Administering E-Selectin

The invention is a method and composition for inhibiting or treating symptoms of inflammatory demyelination or inflammation associated with autoimmune disorders. This is accomplished by administering recombinant E-selectin protein intranasally and resulting in E selectin-specific regulatory T-cells. These regulatory T-cells suppress activation of blood vessels where E-selectin is normally expressed by the localized production of immunosuppressive cytokines, modulating the actions of otherwise pro-inflammatory T cells that can aberrantly cause demyelination of neurons, which leads to diseases like MS.

Potential Commercial Applications: Competitive Advantages:
In addition to MS, potentially effective in treating other autoimmune disorders such as rheumatoid arthritis, type 1 diabetes, psoriasis, and those that affect blood vessels. 

Development Stage:
In vitro and in vivo data are available.


Jacqueline Shukaliak-Quandt (NINDS)  ➽ more inventions...

Intellectual Property:
US Application No. 60/828,732
PCT Application No. PCT/US2007/021682
US Application No. 12/444,854

Licensing Contact:
Admin. Licensing Specialist (ALS),

OTT Reference No: E-153-2005-0
Updated: Jun 16, 2010